Company: CERO
Filing Date: 2025-01-21
Form Type: S-1/A
Source: 0001213900-25-004742
Chunk: 126

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-21
Form: S-1/A
Chunk 126
---
    77,046,502 |   |
| Stock subscription                                                                   
 receivable                                                                           |     |         |    (2,073,607 | ) |     |          |       (78,750 | ) |     |            |       (78,750 | ) |
| Accumulated deficit                                                                  |     |         |   (71,589,745 | ) |     |          |   (71,589,745 | ) |     |            |   (71,589,745 | ) |
| Total stockholders’                                                                  
 equity (deficit)                                                                     |     |         |    (3,702,425 | ) |     |          |       306,952 |   |     |            |     8,611,752 |   |
| Total capitalization                                                                 |     | $       |    (3,702,425 | ) |     | $        |       306,952 |   |     | $          |     8,611,752 |   |

The number of shares of Common Stock that will be outstanding after this offering is based on 1,475,426 shares of Common Stock outstanding as of September 30, 2024 (giving retroactive effect to the Reverse Stock Split), and excludes:

| ● | 26,575 shares of Common Stock underlying outstanding options (61,080 
 shares as of January 8, 2025);                                       |

| ● | 45,151                                                                                                                           
 shares of Common Stock issuable under our 2016 Plan and our 2024 Plan, which includes 45,151 shares of Common Stock reserved for 
 issuance under our 2016 Plan and our 2024 Plan (408,801 shares as of January 8, 2025);                                           |

| ● | 5,272                                                                                      
 shares of Common Stock issuable under our 2024 ESPP, which includes 5,272 shares of Common 
 Stock reserved for issuance under our 2024 ESPP (5,272 shares as of January 8, 2025);      |

| ● | 95,175                                                                                                                           
 shares of Common Stock issuable upon the exercise of Public Warrants and Private Placement Warrants (95,186 shares as of January 
 8, 2025);                                                                                                                        |

| ● | 87,879                                                                                                                               
 shares of Common Stock issuable upon the exercise of Common Warrants issued in the offerings of our Series A Preferred Stock, Series 
 B Preferred Stock and